wildpixel/iStock via Getty Images Moderna ( MRNA ) is in the early stages of developing a hantavirus vaccine, though its availability could be years away. Shares are up ~14% in Friday afternoon trading. Hantavirus has received renewed interest recently amid an outbreak of the virus on the MV Hondius that killed three people and infected at least six others, according to the World Health Organizati...
wildpixel/iStock via Getty Images Moderna ( MRNA ) is in the early stages of developing a hantavirus vaccine, though its availability could be years away. Shares are up ~14% in Friday afternoon trading. Hantavirus has received renewed interest recently amid an outbreak of the virus on the MV Hondius that killed three people and infected at least six others, according to the World Health Organization. Moderna, best known for developing an mRNA COVID-19 vaccine, has done early-stage hantavirus vaccine research in coordination with the U.S. Army Medical Research Institute of Infectious Diseases, the company told Bloomberg News . In addition, the biotech has also partnered with the Vaccine Innovation Center at Korea University College of Medicine. Its current research started before the cruise ship outbreak. " These efforts are early-stage and ongoing and reflect Moderna's broader responsibility to develop countermeasures against emerging infectious diseases," Moderna said . An NBC News report stated that prior efforts to develop a hantavirus vaccine have stalled because outbreaks tend to be rare and occur in poor countries where pharmas are less likely to invest. "Our funding agencies don’t put a lot of money into this, because it's likely not to cause the next epidemic or pandemic," Sabra Klein, a Johns Hopkins Bloomberg School of Public Health molecular microbiology and immunology professor, told the news outlet . That likely means a hantavirus vaccine could be years—perhaps a decade or more—away, barring massive government investment and support that was seen during Operation Warp Speed for COVID-19 vaccine development, according to EnsiliTech co-founder Matt Slade. That company began work on a hantavirus vaccine, using an mRNA background, 15 years ago. More on Moderna Moderna's Post-COVID Collapse: Pipeline Risks & Cash Burn Explained Moderna, Inc. (MRNA) Q1 2026 Earnings Call Transcript Moderna, Inc. 2026 Q1 - Results - Earnings Call Presentation FDA halts publica...
Wedbush analyst Dan Ives may be best known for his vocal support of Nvidia and Tesla , but on Friday morning, he reminded investors that he is just as bullish on another mega-cap tech name: Apple (NASDAQ: AAPL) . In a fresh note, Ives lifted his price target on Apple stock from $350 to $400 -- the highest figure any major firm has set on the iPhone maker. From a recent share price of about $293, t...
Wedbush analyst Dan Ives may be best known for his vocal support of Nvidia and Tesla , but on Friday morning, he reminded investors that he is just as bullish on another mega-cap tech name: Apple (NASDAQ: AAPL) . In a fresh note, Ives lifted his price target on Apple stock from $350 to $400 -- the highest figure any major firm has set on the iPhone maker. From a recent share price of about $293, that implies upside of nearly 37%. What has the analyst so bullish? Ives called Apple "the sleeping tech giant about to see a major inflection point in growth" as the company prepares to unveil its long-awaited artificial intelligence (AI) strategy at WWDC 2026 in June. For investors who have grown impatient with Apple's slow pace on AI, it's a compelling argument. And recent results suggest Cupertino doesn't necessarily need a flashy AI moment to keep its current momentum going. But it would certainly help. Continue reading
Shares of Cerence ( CRNC ) fell 8% on Friday after the company reported second-quarter results. Cerence posted a Q2 GAAP EPS of $0.04. Revenue declined 17.7% year over year to $64.2M, though it beat analyst estimates by $3.33M. The company said adjusted EBITDA reached $7.2M, while free cash flow totaled $13.6M. "We believe we have a durable growth profile over time, supported by disciplined execut...
Shares of Cerence ( CRNC ) fell 8% on Friday after the company reported second-quarter results. Cerence posted a Q2 GAAP EPS of $0.04. Revenue declined 17.7% year over year to $64.2M, though it beat analyst estimates by $3.33M. The company said adjusted EBITDA reached $7.2M, while free cash flow totaled $13.6M. "We believe we have a durable growth profile over time, supported by disciplined execution, strong cash generation, and a continued focus on profitable growth. Based on our strong performance and improved visibility, we are raising the midpoints of our full-year revenue, adjusted EBITDA, and free cash flow guidance,” CEO Brian Krzanich Cerence bumped the lower end of its guidance to $305M from the previous target of $300M, which it says puts the midpoint of its full-year revenue guidance at $312.5M. More on Cerence Cerence Inc. 2026 Q2 - Results - Earnings Call Presentation Cerence Sees Initial Wins With xUI Platform But I'm Skeptical Of Durability (Downgrade) Cerence GAAP EPS of $0.04, revenue of $64.2M beats by $3.33M Cerence Q2 2026 Earnings Preview Seeking Alpha’s Quant Rating on Cerence
sasacvetkovic33/E+ via Getty Images Devon Energy ( DVN ) up 0.8% in Friday's trading as Jefferies upgraded shares to Buy from Hold with a $62 price target, raised from $53, saying the stock has multiple catalysts for relative outperformance following completion of the Coterra acquisition, but attracting long-only capital requires a clearer focus on durable core assets. Divesting non-core assets co...
sasacvetkovic33/E+ via Getty Images Devon Energy ( DVN ) up 0.8% in Friday's trading as Jefferies upgraded shares to Buy from Hold with a $62 price target, raised from $53, saying the stock has multiple catalysts for relative outperformance following completion of the Coterra acquisition, but attracting long-only capital requires a clearer focus on durable core assets. Divesting non-core assets could eliminate debt and boost returns, according to Jefferies analysts led by Lloyd Byrne, who said Devon's ( DVN ) Marcellus asset could be sold at a premium to the stock's current multiple; assuming 4.5x-5.5x EBITDA of ~$1.75B, proceeds could potentially retire $8.5B in year-end 2026 outstanding debt. The analysts showed distributable cash flows that support their upside scenario, which highlights the risk/reward associated with a de-levered balance sheet and a lower cost of capital; following the sale close, they expect Devon ( DVN ) would return ~100% of free cash flow to shareholders, which after the base dividend would leave ~$7B, or 13% of market cap at $50/share, at $75 WTI. Jefferies modeled that Devon ( DVN ) will deliver ~20% more cost savings than anticipated in the company's 2025 savings plan on a standalone basis by year-end 2027 and incorporated the full ~$1B of Coterra synergies going forward, with potential for upside. More on Devon Energy Devon-Coterra Merger: Good And Bad Devon Energy: The Easy Money Has Been Made Devon Energy: Merger Deal, Iran War, Price Tailwinds
Badenoch’s statement came after the Conservatives won back Westminster and Wandsworth councils in London Elections 2026 live: latest news updates Full results from England, Scotland and Wales Kemi Badenoch has claimed that the Conservatives are “coming back” after winning back Westminster and Wandsworth councils from Labour in London, despite her party suffering significant losses throughout Engla...
Badenoch’s statement came after the Conservatives won back Westminster and Wandsworth councils in London Elections 2026 live: latest news updates Full results from England, Scotland and Wales Kemi Badenoch has claimed that the Conservatives are “coming back” after winning back Westminster and Wandsworth councils from Labour in London, despite her party suffering significant losses throughout England in Thursday’s elections. The party also saw off a threat from Reform in Bexley. But the Tories suffered a series of losses in Essex, where Badenoch herself is an MP, losing 13 seats while Reform gained 52. They held on to Harlow, securing all 11 district council seats available. Continue reading...
The technology sector is leading the stock market this year, and for some of the best-performing tech stocks, it may be time to take profits. The IBD Smart NYSE + Nasdaq Tables show the tech sector's dominance, with the Computer, Chips, and Electronics sectors up 53% to 141% year to date. Many technology stocks have already climbed 20% or more from their most recent buy points.
The technology sector is leading the stock market this year, and for some of the best-performing tech stocks, it may be time to take profits. The IBD Smart NYSE + Nasdaq Tables show the tech sector's dominance, with the Computer, Chips, and Electronics sectors up 53% to 141% year to date. Many technology stocks have already climbed 20% or more from their most recent buy points.
Vaccine Trade Returns? Moderna Working On Hantavirus Shot Sends Shares Higher Moderna is out with timely news that it is working on early-stage research on vaccines targeting hantaviruses. The news comes as a Spanish woman has been hospitalized for a suspected infection, while a hantavirus cluster has ravaged a Dutch-flagged cruise ship, with five confirmed and three suspected cases of hantavirus....
Vaccine Trade Returns? Moderna Working On Hantavirus Shot Sends Shares Higher Moderna is out with timely news that it is working on early-stage research on vaccines targeting hantaviruses. The news comes as a Spanish woman has been hospitalized for a suspected infection, while a hantavirus cluster has ravaged a Dutch-flagged cruise ship, with five confirmed and three suspected cases of hantavirus. Three deaths have been reported so far. Bloomberg reports that Moderna is collaborating with the U.S. Army Medical Research Institute of Infectious Diseases on hantavirus vaccine research and is also working with Korea University College of Medicine's Vaccine Innovation Center on a potential vaccine. "These efforts are early-stage and ongoing and reflect Moderna's broader responsibility to develop countermeasures against emerging infectious diseases," Moderna said. Moderna said its work on hantavirus vaccines began before the cruise ship Hondius reported an outbreak while anchored off the coast o f Cape Verde , on the west coast of Africa, last week. Anais Legand, a technical officer at the World Health Organization (WHO), provided an update earlier today stating that all remaining passengers on the Hondius have left the ship without symptoms. "They will be asked to take their temperature every single day for 42 days. They will be asked to check every day for other symptoms like feeling unwell or a headache," Legand said, adding, "They will be provided with someone to contact. If they're not feeling well, it's up to the national authorities where people will go next." WHO Emergencies Communications Lead Nyka Alexander stated in a livestreamed update earlier that "the risk to the public remains low." Hantaviruses are zoonotic viruses that naturally infect rodents and can occasionally spread to people. Here’s what you need to know about #hantavirus : What they are, how they spread, the symptoms, and how to prevent infection pic.twitter.com/pduUjlwl2j — World Health Organizat...